No Data
No Data
Stifel Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Cuts Target Price to $30
Cullinan Oncology Price Target Maintained With a $33.00/Share by HC Wainwright & Co.
H.C. Wainwright Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $33
Cullinan Therapeutics Reports 2024 Financial Results and Updates
William Blair Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating
TD Cowen Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating